Abstract
Glioblastoma(GBM) is most common brain tumor in adults. Currently standard treatments have limited effect to increase the survival, because there are still largely unclear mechanisms in glioblastoma development. miR-223 was involved in various types of cancer, however, the function of miR-223-3p in GBM was still unclear. In our study, real-time PCR was performed to exam the expression level of miR-223-3p and NLRP3 (Nucleotide-binding oligomerization domain(NOD)-like receptor family PYRIN domain containing-3) in GBM tissues. Following that, mimic or inhibitor of miR-223-3p were used to modulate miR-223-3p expression in GBM cell lines respectively. Then, we analyzed cell proliferation and migration by cell counting kit and transwell assay. Further, western blot was performed to detect several inflammation-associated cytokines level in GBM cell lines. We found that miR-223-3p was decreased but NLRP3 was increased in GBM tissues. Treatment with miR-223-3p mimic inhibits cell proliferation and migration via decreasing several inflammation-associated cytokines, including interleukin-1β (IL-1β), monocyte chemoattractant protein-1 (MCP-1), IL-8 and IL-18. Importantly, these effects induced by miR-223-3p could be attenuated by NLRP3 ove...Continue Reading
Citations
Nov 6, 2018·Cancer Science·Chen YangHaowen Jiang
Mar 7, 2019·Bioscience Reports·Fernando J VellosoRicardo G Correa
Oct 28, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yankai WeiHong Nian
Jan 23, 2019·Aging·Wen XiaoJinchun Xing
Mar 12, 2020·Aging·Li-Li SunXiao-Qiang Li
Sep 12, 2019·Scientific Reports·Rashmi P KulkarniKhaled Machaca
Sep 12, 2020·Journal of Neuro-oncology·Andrew MorokoffAndrew H Kaye
Jul 17, 2020·Frontiers in Cell and Developmental Biology·Nilisha FernandoRiccardo Natoli
May 24, 2019·Frontiers in Pharmacology·Gulcin TezcanSvetlana F Khaiboullina
Feb 2, 2020·Scientific Reports·Mohammad Reza KalhoriMasoud Soleimani
Feb 27, 2020·Cancer Cell International·Jingyu WangYonghui Su
Sep 8, 2020·Cancer Biomarkers : Section a of Disease Markers·Xuan ZouWei Zhu
Mar 9, 2019·Inflammation·Hai-Chao DongPeng Li
Nov 5, 2020·Journal of Cellular and Molecular Medicine·Fu-Quan LongQian-Qiu Wang
Feb 5, 2021·Epigenomics·Sruti ChandraMelanie Ehrlich
Apr 17, 2021·BioMed Research International·Jing ZouNing Sun
May 18, 2021·Frontiers in Immunology·Manish MuhuriGuangping Gao
May 2, 2021·FEBS Open Bio·Yu Zheng WuPak Cheung Ng
Jul 12, 2021·Arthritis Research & Therapy·Jana BohatáBlanka Stibůrková
Aug 31, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Junfu GuoWenna Chen
Oct 4, 2020·Experimental and Molecular Pathology·Omidvar RezaeiSoudeh Ghafouri-Fard
Oct 1, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Sheyda HoushmandfarMohammad-Reza Mahmoudian-Sani
Dec 2, 2021·Molecular Biology Reports·Ufuk UnalHakan Vuruskan